Key Takeaways
- Sutro Biopharma has replaced its CEO and cut nearly half of its workforce as part of a major restructuring.
- The company is deprioritizing its lead candidate, luveltamab tazevibulin, to focus on new ADC programs.
- Financial projections indicate that the restructuring will extend Sutro’s cash runway into late 2026.
Major Changes at Sutro Biopharma
Sutro Biopharma is undergoing significant changes as it seeks to enhance its financial stability. In a recent strategic shift, the company announced the dismissal of CEO Bill Newell. His departure, described as a mutual agreement with the board, coincides with a substantial reduction in workforce, with nearly 50% of employees being let go to streamline operations. This measure is part of Sutro’s decision to deprioritize its lead candidate, luveltamab tazevibulin (luvelta).
Luvelta, an antibody-drug conjugate targeting FolRα, was being evaluated in multiple clinical trials, including those for platinum-resistant ovarian cancer and non-small cell lung cancer, as well as a trial for pediatric acute myeloid leukemia. Despite reported promising data as recently as December, with a 32% response rate in initial studies, Sutro’s strategic portfolio review suggested reallocating resources toward its next-generation assets, including an exatecan tissue factor ADC and other dual-payload ADC programs.
Jane Chung, who has stepped into the role of CEO, asserted that this focus on high-value candidates would enable Sutro to tackle complex biological challenges in oncology. The company now aims to file three Investigational New Drug (IND) applications over the next three years, with plans for the exatecan ADC submission expected in late 2023. Subsequent programs include an integrin beta-6 ADC anticipated to enter clinical trials in 2024, and a dual-payload ADC projected for IND submission in 2027.
Accompanying these developments is a significant alteration in Sutro’s infrastructure. The company plans to vacate its drug substance manufacturing facility in San Carlos, California, by year-end, as it transitions to utilize external manufacturing capacity. This move supports the shift to focus on its newer ADC programs while reducing operational costs.
Financially, Sutro entered the year with $316.9 million in hand, and leadership forecasts suggest that the restructuring will allow the company to extend its financial runway until the fourth quarter of 2026. This financial projection excludes potential milestone payments from ongoing collaborations with partners such as Ipsen and Astellas, which could yield up to $2 billion in future milestones.
Overall, the restructuring signifies a pivotal moment for Sutro Biopharma, reflecting a strategic pivot from previous ambitions tied to luvelta, enabling the company to concentrate on promising avenues in its ADC portfolio while navigating the operational reductions necessary for long-term sustainability.
The content above is a summary. For more details, see the source article.